Autologous Cd8+ T-Cells, Transduced With Mage-A1 Directed Tcr
Uveal Melanoma
Explore 61 assets in Uveal Melanoma →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03068624CT.gov Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Cd8+ T-Cells, Transduced With Mage-A1 Directed Tcr (this asset) | M.D. Anderson Cancer Center | P1 | CC · 41 |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Darovasertib | IDEAYA Biosciences | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2/3 | BB |
| Sargramostim | Thomas Jefferson University | P3 | BB |
| Pembrolizumab | BioInvent International AB | P2/3 | BB |
| Gm-Csf | Ahmad Tarhini | P2 | BB |
| Melphalan | Vastra Gotaland Region | P3 | BB |
+42 more in the Uveal Melanoma cohort
Other indications for Autologous Cd8+ T-Cells, Transduced With Mage-A1 Directed Tcr
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P2 | CCC · 55 |
| Metastatic Melanoma | — | P2 | CCC · 50 |
| Cancer | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Cd8+ T-Cells, Transduced With Mage-A1 Directed Tcr in Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-cd8-t-cells-transduced-with-mage-a1-directed-tcr-uveal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →